Published in Prostate on March 22, 2011
(18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. Oncol Lett (2015) 0.85
The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Ann Epidemiol (2015) 0.77
Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study. Oncol Lett (2013) 0.76
Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA. Rev Urol (2010) 0.75
Prostate-specific antigen rising in Iranian men in correlation with body mass index, fasting blood sugar and blood lipid profile. J Nephropathol (2016) 0.75
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer Causes Control (2016) 0.75
PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis. J Cancer (2017) 0.75
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med (1996) 5.68
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Comparison of self-reported and measured BMI as correlates of disease markers in US adults. Obesity (Silver Spring) (2007) 3.76
The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol (1993) 3.66
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol (2008) 2.79
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol (2009) 2.09
A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc (2002) 2.04
Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.91
The association of body mass index and prostate-specific antigen in a population-based study. Cancer (2005) 1.85
A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst (2005) 1.75
Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab (2008) 1.74
Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev (2006) 1.65
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer (2006) 1.60
'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol (1994) 1.56
Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate (2009) 1.56
Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol (2006) 1.43
Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev (2008) 1.32
Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev (2009) 1.25
Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res (2005) 1.24
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol (2005) 1.22
The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int (2009) 1.18
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev (2005) 1.13
Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care (2008) 1.12
Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology (2003) 1.06
Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate (2008) 1.04
The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control (2010) 0.97
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur J Cancer (2007) 0.94
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol (2009) 0.92
Obesity-PSA relationship: a new formula. Prostate Cancer Prostatic Dis (2009) 0.90
Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am (2008) 0.90
Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology (2008) 0.90
Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol (2007) 0.86
Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men. Int J Urol (2008) 0.79
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol (2008) 2.79
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst (2002) 2.54
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
Circumcision and the risk of prostate cancer. Cancer (2012) 2.48
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res (2011) 2.34
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Prostate cancer in men using testosterone supplementation. J Urol (2005) 2.12
Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev (2007) 2.11
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer (2008) 1.94
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol (2010) 1.86
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Incidence of primary urethral carcinoma in the United States. Urology (2006) 1.78
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res (2009) 1.69
Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer (2005) 1.69
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer (2006) 1.67
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol (2012) 1.60
Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst (2011) 1.58
Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.58
Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol (2010) 1.57
Effect of collecting duct histology on renal cell cancer outcome. J Urol (2009) 1.54
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 1.54
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.51
Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res (2009) 1.49
Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer (2007) 1.47
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet (2011) 1.47
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol (2007) 1.42
Genetic etiology of hereditary prostate cancer. Front Biosci (2007) 1.41
Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am J Epidemiol (2002) 1.39
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol (2010) 1.36
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.34
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control (2007) 1.30
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res (2009) 1.27
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol (2008) 1.23
Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res (2009) 1.22
Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate (2008) 1.21
Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol (2005) 1.21
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab (2005) 1.21
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet (2007) 1.20
Vitamin D pathway gene variants and prostate cancer prognosis. Prostate (2010) 1.20
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Semiparametric models of time-dependent predictive values of prognostic biomarkers. Biometrics (2009) 1.17
Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control (2009) 1.15
Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control (2002) 1.14
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14